China
Africa
Explore chapters and articles related to this topic
A Perspective of Ultrasound-Related Micro/Nano Cancer Therapy
Published in Hala Gali-Muhtasib, Racha Chouaib, Nanoparticle Drug Delivery Systems for Cancer Treatment, 2020
Tingting Zheng, Yun Chen, Jiao Peng, Yu Shi, Jun Zhang, Haitao Xiao, Xiangmei Chen, Yongcan Huang, Tao Pei, Zhuxia Zhang, Xue Zhang, Xiaohe Bai, Li Liu, Jinrui Wang
Sonodynamic therapy (SDT) is one of the most important ultrasound-related cancer treatments [187–189]. Compared with photodynamic therapy (PDT), acoustic waves can penetrate deeper into tissues than laser; therefore SDT has attracted more attention in preclinical studies. There are three key points to trigger SDT. These include ultrasound, sonosensitizers, and oxygen molecules [13, 187, 190, 191].
Sonodynamical reversion of immunosuppressive microenvironment in prostate cancer via engineered exosomes
Published in Drug Delivery, 2022
Dingyi Wang, Zhuo Wan, Qian Yang, Jianmei Chen, Yunnan Liu, Fan Lu, Jie Tang
Sonodynamic therapy (SDT) employs ultrasound in combination with sonosensitizers (such as Chlorin e6, Ce6) to induce ROS locally (McHale et al., 2016). Besides, SDT was reported to improve antigen presentation ability, which may promote the immune activation and infiltration of T cells (Peng et al., 2018; Huang et al., 2021). The combination of SDT with an immunoadjuvant, such as the agonist of toll-like receptors 7 and 8 (TLR7/8), resiquimod (R848), is hypothesized to induce stronger anti-tumor immunity. However, both the sensitizing agent and R848 have disadvantages such as poor water solubility, easy aggregation, low bioavailability, poor tumor specificity, and fast clearance in vivo, etc. Thus, it is a critical issue to explore a promising local drug delivery strategy for codelivery both sonosensitizers and R848.
High intensity focused ultrasound for the treatment of solid tumors: a pilot study in canine cancer patients
Published in International Journal of Hyperthermia, 2022
Jennifer Carroll, Sheryl Coutermarsh-Ott, Shawna L. Klahn, Joanne Tuohy, Sabrina L. Barry, Irving C. Allen, Alayna N. Hay, Jeffrey Ruth, Nick Dervisis
To date the use of HIFU for the treatment of canine cancer is scarce and limited to small retrospective case series or reports [26–30]. Ryu et al. evaluated the use of HIFU for the treatment of solid tumors in canines and found that 5/10 dogs treated experienced relief of their clinical signs and 4/10 dogs had documented tumor regression of varying degrees. Side effects were mild consisting of erythema, superficial skin ulceration, and enteritis, all of which were self-limiting [27]. Another study investigated the use of sonodynamic therapy using an anti-cancer micelle and HIFU combination for the treatment of 4 different tumor histologies. Treatment resulted in improvement in patient pain scores and function [28]. Kopelman et al. used MRI guided Focused Ultrasound with thermometry for the treatment of a large hepatocellular adenoma in a dog over the course of 4 separate sessions. Finally, Ranjan et al., reported on a case of a large oral tumor treated with HIFU, resulting in tumor remission and proliferation of T-cells around the treated tumor [29].
‘Mito-Bomb’: a novel mitochondria-targeting nanosystem for ferroptosis-boosted sonodynamic antitumor therapy
Published in Drug Delivery, 2022
Jianxin Wang, Zhiyu Zhao, Yan Liu, Xinyu Cao, Fuxin Li, Haitao Ran, Yang Cao, Changjun Wu
Sonodynamic therapy (SDT), as a new treatment strategy for tumor treatment, has overcome the limitation of light penetration depth and has the advantages of minimally invasive, no radiation, and low cost (Lafond et al., 2019; Son et al., 2020; Jiang et al., 2022). Although the detailed mechanism of SDT is still unclear, it is evident that low-intensity ultrasound will lead to excessive reactive oxygen species (ROS) production when interacting with sonosensitizers, thus enhancing cytotoxicity (Son et al., 2020; Zhang et al., 2021b).In addition, an essential factor affecting SDT is the subcellular localization of sonosensitizers. Mitochondria, as the site of cell energy metabolism, also participate in various types of cell death, which has attracted the attention of researchers (Pathania et al., 2009; Guo et al., 2021). Previous studies have shown that destroying mitochondrial integrity can transmit apoptotic cell signals and initiate apoptosis. Mitochondria-targeting SDT resulted in more tumor cell apoptosis than SDT with nonselective subcellular distribution (Zong et al., 2016; Qu et al., 2020; Han et al., 2021). Therefore, mitochondria-targeting SDT is considered a more effective and promising treatment for apoptosis. However, due to the inherent anti-apoptotic ability of triple-negative breast cancer tumor (TNBC) cells, the overall effectiveness of various treatment methods, including SDT and the improvement of patient survival rate, are still not ideal (Sun et al., 2021; Yao et al., 2021). There is an urgent need to develop non-apoptotic therapies to disrupt the anti-apoptotic mechanisms of TNBC cells.